Verastem, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
MA
Business Address
117 KENDRICK STREET, NEEDHAM, MA, 02494
Mailing Address
117 KENDRICK STREET, NEEDHAM, MA, 02494
Phone
(781) 292-4200
Fiscal Year End
1231
EIN
273269467
Financial Overview
FY2025
-$87.37M
Net Income
$246.44M
Total Assets
$189.25M
Total Liabilities
$57.37M
Stockholders' Equity
$204.99M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | March 27, 2026 | View on SEC |
| 4 Insider stock transaction report | March 23, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 10-K Annual financial report | March 4, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
Annual Reports
10-K
March 4, 2026
- Positive early results from the Phase 2 RAMP 201 study of Avutometinib in recurrent Low-Grade Serous Ovarian Cancer (LGSOC).
- Continued advancement and patient enrollment in the crucial Phase 3 RAMP 301 study for Avutometinib in KRAS-mutated Non-Small Cell Lung Cancer (NSCLC).
Insider Trading
STRONG SELL
6 insiders
23 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.